DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucolipidosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucolipidosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucolipidosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mucolipin TRP cation channel 1 (MCOLN1) — MCOLN1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1s,2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7MGL · 2.9 Å · ligand N-{(1S,2S)-2-[4-(2-methoxyphenyl)piperazin-1-yl]cyclohexyl}benzenesulfonamide (ZB4). Experimental structure, not a prediction.
What the evidence adds up to
Mucolipidosis comprises several distinct lysosomal storage disorders with different genetic causes. Mucolipidosis type IV (MLIV) results from mutations in MCOLN1, which encodes mucolipin-1, a lysosomal membrane protein. In cell studies from 2006, expression of wild-type mucolipin-1 rescued aberrant lactosylceramide trafficking in MLIV cells, but mucolipin-1 mistargeted to the plasma membrane or mutated in its predicted ion pore did not. The correct lysosomal localisation and an intact ion pore are both required for mucolipin-1 function in the late endocytic pathway. No drug treatment was tested in that study.
Mucolipidosis II (I-cell disease) and mucolipidosis III (pseudo-Hurler polydystrophy) are caused by deficiency of uridine diphosphate-N-acetyl-glucosamine: lysosomal enzyme precursor N-acetyl-glucosamine-phosphate transferase. A 1983 complementation analysis showed that both disorders are genetically heterogeneous; mucolipidosis II was identical to one of three mucolipidosis III complementation groups (ML IIIA). The transferase is apparently a multicomponent enzyme. In a 2019 study of three Brazilian patients with mucolipidosis III gamma, the residual GlcNAc-1-phosphotransferase activity was sufficient to maintain B-cell functions, suggesting a less severe immune impairment than in ML II. No therapy was evaluated.
Clinical descriptions from 1972 and 1991 document the natural history. A 14-year-old Japanese boy with a new type of mucolipidosis had coarse facies, dysostosis multiplex, neurologic deterioration, corneal clouding, macular cherry red spot, beta-galactosidase deficiency, and glycopeptiduria. Among five MLIV patients from three Ashkenazi-Jewish families, presenting symptoms were hypotonia, developmental delay, corneal clouding, and puffy eyelids. None progressed beyond a developmental age of 15 months. One patient died of aspiration at 17 years; the oldest reached puberty at 20 years, developed coarse face at 30 years, and was alive at 32 years. A 2001 report described an African American MLIV patient diagnosed after penetrating keratoplasty, with intracytoplasmic inclusions in corneal endothelium, a finding not previously reported. No treatment was described in any of these natural history reports.
No drug has been tested in patients with any form of mucolipidosis in these abstracts. What is missing is any clinical trial of a pharmacological agent, any attempt to target the underlying enzyme deficiency or ion channel defect in patients, and any stratification of patients by genotype or residual enzyme activity to identify who might benefit. Funding for such trials and development of small molecules or enzyme replacement remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Traffic · 2006 · 162 citations · open access
Mucolipin‐1 Is a Lysosomal Membrane Protein Required for Intracellular Lactosylceramide Traffic
AbstractMucolipin-1 is a membrane protein encoded by the gene MCOLN1, mutations in which result in the lysosomal storage disorder mucolipidosis type IV (MLIV). Efficient lysosomal targeting of mucolipin-1 requires di-leucine motifs in both the N-terminal and the C-terminal cytosolic tails. We have shown that aberrant lactosylceramide trafficking in MLIV cells may be rescued by wild-type mucolipin-1 expression but not by mucolipin-1 mistargeted to the plasma membrane or by lysosome-localized mucolipin-1 mutated in its predicted ion pore-selectivity region. Our data demonstrate that the correct localization of mucolipin-1 and the integrity of its ion pore are essential for its physiological function in the late endocytic pathway.
The Tohoku Journal of Experimental Medicine · 1972 · 70 citations · open access
A New Type of Mucolipidosis with β-Galactosidase Deficiency and Glycopeptiduria
AbstractClinical, biochemical and electron microscopic studies on a patient of a new type of mucolipidosis are described. The patient is a 14-year-old Japanese boy who has coarse facies, dysostosis multiplex, neurologic deterioration, corneal clouding, macular cherry red spot, β-galactosidase deficiency, glycopeptiduria, and vacuolated cells in hepatic parenchyma, renal glomeruli, renal bone marrow and peripheral lymphocytes.
American Journal of Medical Genetics · 1991 · 69 citations
Mucolipidosis type IV: Clinical manifestations and natural history
AbstractThe clinical manifestations and psychomotor development of five patients with mucolipidosis IV (MLIV) from three Ashkenazi-Jewish families are reported. The presenting symptoms were hypotonia, developmental delay, corneal clouding, and puffy eyelids. Four of the patients had convergent strabismus and none progressed beyond a developmental age of 15 months. One patient died of aspiration at 17 years while the oldest patient entered puberty at 20 years, developed a coarse face at 30 years, and is now 32 years old. Histopathological studies in four patients showed storage changes characteristic of MLIV.
Journal of Clinical Investigation · 1983 · 47 citations · open access
Mucolipidosis II and III. The genetic relationships between two disorders of lysosomal enzyme biosynthesis.
AbstractThe genetic relationships between the multiple variants of mucolipidosis II (I-cell disease) and mucolipidosis III (pseudo-Hurler polydystrophy) were investigated with a sensitive genetic complementation analysis procedure. These clinically distinct disorders have defects in the synthesis of a recognition marker necessary for the intracellular transport of acid hydrolases into lysosomes. Both disorders are associated with an inherited deficiency of a uridine diphosphate-N-acetyl-glucosamine: lysosomal enzyme precursor N-acetyl-glucosamine-phosphate transferase activity. We had previously shown that both disorders are genetically heterogeneous. Complementation analysis between mucolipidosis II and III fibroblasts indicated an identity of mucolipidosis II with one of the three mucolipidosis III complementation groups (ML IIIA), suggesting a close genetic relationship between these groups. The presence of several instances of complementation within this group suggested an intragenic complementation mechanism. Genetic complementation in heterokaryons resulted in increases in N-acetyl-glucosamine-phosphate transferase activity, as well as in the correction of lysosomal enzyme transport. This resulted in increases in the intracellular levels of several lysosomal enzymes and in the correction of the abnormal electrophoretic mobility pattern of intracellular beta-hexosaminidase. The findings demonstrate that a high degree of genetic heterogeneity exists within these disorders. N-acetyl-glucosamine-phosphate transferase is apparently a multicomponent enzyme with a key role in the biosynthesis and targeting of lysosomal enzymes.
AbstractFive new cases of Mucolipidosis IV are related and the seven cases in the literature reviewed. Neurological signs of the disorder and the value of skin and conjuncitival biopsies for its diagnosis are emphasized. Arguments in favour of a recessive autosomic inheritance are brought forth. The disease does not affect exclusively Jewish people. In two cases absence of oligosacchariduria was demonstrated.
Mucolipidosis IV in an African American Patient with New Findings on Electron Microscopy
AbstractPURPOSE: We report an unusual case of mucolipidosis IV in a patient of African ancestry, with intracytoplasmic inclusions of the corneal endothelium found on electron microscopy. METHOD: Clinical description with light and electron microscopy. RESULTS: We describe a case of mucolipidosis IV diagnosed in a patient of African ancestry after penetrating keratoplasty. Electron microscopic evaluation revealed intracytoplasmic inclusions in both the corneal epithelium and endothelium. CONCLUSION: The diagnosis of mucolipidosis in a patient of African ancestry is unusual, as this genetic disorder is found predominantly in individuals of Jewish descent. Corneal endothelial involvement in mucolipidosis IV has not previously been reported.
AbstractTo the Editor.— The short report of Morrison and Kerr1 entitled "Growth Plate: Roentgenologic Findings in a Case of Tyrosinosis" deserves some comments. In addition to phenylketonuria and homocystinuria which were mentioned by the authors, roentgenologic bony changes were shown recently in a 5-month-old boy with mucolipidosis II (I-cell disease).2 Alkaline phosphatase was found to be elevated, and calcium and phosphorus levels were somewhat decreased in most of these cases. With the addition of roentgenologic findings one can be sure that all of these patients had rickets.
Genetics and Molecular Biology · 2019 · 0 citations · open access
Humoral immune response in adult Brazilian patients with Mucolipidosis III gamma
AbstractMucolipidosis II and III (ML II and III) alpha/beta and ML III gamma are lysosomal diseases caused by GlcNAc-1-phosphotransferase deficiency. Previous data indicate that MLII patients have functionally impaired immune system that contributes to predisposition to infections.We evaluated the immunological phenotype of three Brazilian patients with ML III gamma. Our data suggest that the residual activity of GlcNAc-1-phosphotransferase in patients with ML III gamma is enough to allow the targeting of the lysosomal enzymes required for B-cell functions maintenance.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
